Medisys PLC (MDY) Providing innovative solutions to the rapidly growing point-of-care diagnostic and healthcare worker safety markets. For more than 35 years, companies in the Medisys group have been advancing healthcare through development, manufacture and distribution of revolutionary medical products. The Group's mission is to become a leading worldwide provider of diagnostic systems and medical safety products enabling rapid, cost effective, on-site delivery of healthcare solutions.
For more than three decades, Medisys' primary operating unit, Hypoguard, has been devoted to advancing personal and professional healthcare management. The Company's core focus is diabetes glucose self-monitoring - a rapidly growing market of nearly $5 billion worldwide.
'Medisys-group.com'
'Hypoguard.com'

15/02/2006
Medisys reported a 'considerable improvement' in trading during the first four months of its financial year, and said the business has been cash-flow neutral for the year to date.
The medical products company said competition in its core long-term care blood glucose monitoring business has not intensified. A drop in sales amid intense competition in the market caused a fall in sales and profits last year.
Sales volumes have recovered to previous highs by cutting prices and offering various promotions, Medisys reported this morning.
Margin improvements have been achieved faster than originally anticipated, it added. The company has benefited from cost saving measures implemented in the second half of the last financial year and cost reductions for its proprietary biosensor products.
Meanwhile, it has completed the development and manufacturing scale up of the first of the new systems it has designed for Menarini, the fifth largest worldwide branded marketer of blood glucose monitoring systems.
While the launch date is not yet clear, (Around March 1) Medisys predicted that sales of the products will be one of its key revenue growth drivers in the current financial year.


LATEST ON MDY V'S ROCHE COURT CASE
MDY V'S ROCHE COURT CASE Case IS Dismissed. http://www.moneyam.com/InvestorsRoom/posts.php?tid=8721#lastread
My apologies for any one that was on MDY it looks like we have been stitched up like a kipper the sale of Hypoguard blood glucose monitoring business at that price looks like an sp of 3p against the close of 6.4p what can I say no one could have seen this coming a total sell out and that is what I have done.

Tick up coming soon imo.

Plenty of buys today.

For Immediate Release 28 July 2005

Medisys PLC

('Medisys' or 'the Company')

Committed Share Finance Facility

Medisys announces that it has entered into an agreement with the Headstart Group
of funds ('Headstart') under which Headstart will make available to the Company
a committed share finance facility of up to 4,000,000 (the 'Headstart
Facility').

Pursuant to the terms of the Headstart Facility, Headstart has agreed, when
called upon by the Company, to subscribe for, or purchase, new ordinary shares
in the capital of the Company ('Ordinary Shares') to the value of up to, in
aggregate, 4,000,000. The Headstart Facility is available at any time up to 28
January 2008 and is capable of being drawn down by the Company in increments of
up to 125,000. The subscription price for an Ordinary Share shall be equal to
95% of the lowest closing bid price of an Ordinary Share in the ten trading days
following the date on which the Company notifies Headstart that it wishes to
make a draw down under the Headstart Facility.

As announced on 14 July 2005, Hypoguard Limited (a subsidiary of the Company)
has entered into a long-term strategic marketing and distribution agreement with
Menarini to supply the Ferrara blood glucose monitoring system to Menarini to
market under its own brand. It is anticipated that the proceeds from the
Headstart Facility will be used to fund additional working capital needs
associated with Menarini's European launch of Ferrara.

The Headstart Facility is in addition to the Company's overdraft facility of up
to 2,500,000 with the Bank of Scotland. The Company recently agreed with the
Bank of Scotland to reduce the amount available to it under the overdraft
facility from 5,000,000. The Board believes that anticipated cash flows from
operations, together with the available bank facility and the Headstart
Facility, will be sufficient to finance the Group's operations for the
foreseeable future.

In consideration for Headstart making available the Headstart Facility, the
Company has agreed to pay Headstart a one-off fee of 120,000 payable in cash or
by the issue of Ordinary Shares (on the basis of an agreed value per Ordinary
Share of 4.2p, being the closing bid price on 26 July 2005). The Company has
elected to satisfy this fee by issuing 2,857,142 Ordinary Shares to Headstart.
Accordingly, application has been made to the UK Listing Authority for these
shares to be admitted to the Official List and to London Stock Exchange plc for
these shares to be admitted to trading on its market for listed securities. It
is expected that admission to listing will become effective and that dealings in
these shares will commence on 1 August 2005. In addition, the Company has issued
warrants to Headstart granting the right to subscribe for up to 4,000,000
Ordinary Shares at a subscription price of 4.62p per share, being a price equal
to 110% of the closing bid price of the Company's shares on 26 July 2005. Such
warrants are exercisable at any time on or before 27 July 2008.

- Ends -

Lower cost for borrowing "if needed". I am expecting big things once Roche has been put behind us.

Come on MDY

Seems to be good news.

For Immediate Release 29 July 2005


Medisys PLC
('Medisys' or the 'Company')

Directorate Change

Medisys announces that Michael Barry will step down from the Board and resign as
the Company's Chief Financial Officer ('CFO'), with effect from 30 September
2005. Mr Barry is leaving to take up a new opportunity that has arisen for him
outside of the Company.

Donna Glessing, the Company's Financial Controller, will step up as interim CFO.
Ms Glessing has been with the Company for the last seven years and in addition
to her role as the Company's Financial Controller, she is also the Chief
Financial Officer of Hypoguard, the Company's operating subsidiary. Ms Glessing
does not replace Mr Barry on the Board.

David Wong, Chairman commented: 'On behalf of my Board colleagues I would like
to thank Michael for the dedication and commitment he has shown to Medisys since
his appointment in 1999. His skills and leadership have been invaluable and we
wish him the very best for the future.'

- Ends -

Out with the old in with the new. Wait for the big hitters to be announced then we will really see the SP move higher..

Nicholas Piramal plans big diagnostics push
MUMBAI: Homegrown pharma major Nicholas Piramal is planning to scale up its presence in the diagnostics segment.

After its break up with Roche Diagnostics last year, the company has entered into global agreements with three companies exclusively for the diagnostics business.

Nicholas Piramal has signed alliances with Diasys GmbH, a German firm, Hypoguard, a UK-based company part of the Medisys group, and Cholestech, a US-based company. Sources said that the company is likely to regain about 50% of sales within the first year itself.

Last year, while Nicholas Piramals alliance with Roche was active, the company registered sales of Rs 72.6 crore from Roches diagnostic products in India.

In an attempt to fill the vacuum created by the loss of Accu-Chek, a blood glucose monitoring system and a key product in Roches diagnostics portfolio, the Nicholas Piramal-Hypoguard alliance has introduced three products that comprise the blood glucose monitoring portfolio the Advance Micro-draw, QuickTek and the Diascreen range of products.

This range is expected to contribute the largest chunk to the diagnostics portfolio.

Sources said that the products have been launched at an introductory price, which is comparable with that of other blood glucose monitors.

Nicholas Piramal had launched GDX, a more advanced diagnostic system for diabetes, through its alliance with Cholestech. GDX measures the HbA1c, which is an average of blood sugar control for the last three months.

Diasys GmbH of Germany will provide Nicholas Piramal with a range of diagnostic equipment and reagents for the high-end diagnostic portfolio.

The company has also increased the strength of its field force. As Roche took over Nicholas Piramals field force related after the break up, the company has to put in place a new dedicated field force for its diagnostics business.
NICHOLAS PIRAMAL INDIA LTD

Nicholas Piramal Q1 net spurts 11%
JULY 29: Nicholas Piramal India Ltd (NPIL) has registered an 8.8% growth in net sales and 11.1% growth in net profit for the first quarter of FY2006. Net profit grew to Rs 54.13 crore, compared with Rs 48.74 crore in Q1FY05. This resulted in an EPS for the quarter of Rs 2.8 per share, compared with Rs 2.5 per share in Q1FY05. Speaking to FE, Nicholas Piramal chairman Ajay Piramal said the domestic formulations business has grown 14%, compared to last year, when it was badly affected. This growth was also high compared to the industry growth rate of 2.4%. The exports of the company also grew by 49%. The company also discontinued its diagnostics business last year. The company has presence in the US, but this is in the custom manufacturing space, and hence, has not been affected by the recent price pressures, Mr Piramal added. Recovering from the VAT impacted January-March quarter, NPIL delivered over 20% growth in seven of the nine therapeutic areas in which the company operates. Performance was particularly strong in CVS, CNS, anti-diabetic and dermatology segments. During the quarter, NPIL commenced Phase I/II clinical trials in Canada on its oncology lead molecule NP-276. Regulatory permission for trials is awaited from Indian regulatory authorities. In the quarter, Nicholas Piramal also signed a letter of intent for subscribing to a 17.1% equity stake in Biosyntech Inc Canada, a specialty biotech research company.

Going good today up 10%

The Roche case could be settled today in the US MDY looks good for wining or at least settling the case and putting it behind them.

Nice volumes again this morning and another little rise - coming out of the doldrums methinks

baza

baz
You thinks right what ever way the Roche case goes (should here by the end of today) this is going to climb, could be back to 20p+, have you got back on board.

It looks like the Roche case is continuing today thats why theres no news yet, see what happens tomorrow.

Hi Driver - yes got back in this morning with 50,000 @5.5 - perhaps a little late - but I made a few bob last time round - mind still got some way to go before I make up for my earliest forays into MDY.

Baza

baz
I got in just after your run of good luck, first time in, so no lose at 4p. Try to stay in this time with the new announcements and the Roche case being settled soon it will head north or be a bid target.

The Roche hearing has concluded on Monday and the judge is out, mdy are waiting his decision on the out come of the case.

01/08/2005
Plaintiffs appear by counsel, Don Knebel, Lynn Tyler. Defendants appear by counsel, Bob Busby, Shannon Landreth, Jack Matney, Rebecca LeGrand, Aaron Maurer, Barbara McCurdy, Eric Puknys, and Jackie Bennett. Court Reporter is Glen Cunningham. Markman hearing is held and concluded. Matter is taken under advisement.

100% buys so far today.

.......but no tick up !! - yet

Baza

No we got a tick down, nerves have got to the punters awaiting judgment, we may have to wait for up to two weeks before we get any news, just hold fire.

A good post from another board slightly edited by myself, a good summing up of MDYs position at the moment that I agree with.

Liberty is selling very well (expected sales of $13m per annum), MDY have 1m sales via Piramel and an unknown amount of sales via Target, Stada and Menarini to add in. Carnegie have over 8% of MDY shares, Share prices should reflect a shares future position and MDY will have massively more sales than before. MDY also have their own production facility for micro draw which will help margins. The new deals will help margins as production is ramped up. The recent cost cuts (head office and disposal of futura) will help profits. The stronger $ could add 3m in profits alone. All in all MDYs prospects are great (even the recent cash raising deal helps reduce costs as did getting rid of Elans loans). All in all MDY deserve to have a lot higher sp than they have now and I for one have faith we will see 20p plus here one day.